Stockscreener 앱 받기
8.33
8.96%
-0.82
시간 외 거래:
8.33
전일 마감가:
$9.15
열려 있는:
$8.92
하루 거래량:
350.72K
Relative Volume:
1.12
시가총액:
$551.09M
수익:
$555.06M
순이익/손실:
$-39.48M
주가수익비율:
-13.88
EPS:
-0.6
순현금흐름:
$29.05M
1주 성능:
-7.75%
1개월 성능:
-17.44%
6개월 성능:
-29.11%
1년 성능:
+68.97%
1일 변동 폭
$8.16
$8.92
1주일 범위
$8.16
$9.56
52주 변동 폭
$3.90
$14.38
Bioventus Inc Stock (BVS) Company Profile
명칭
Bioventus Inc
전화
(919) 474-6700
주소
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
BVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
8.33 | 551.09M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
124.44 | 215.82B | 41.95B | 13.40B | 6.35B | 7.65 |
|
SYK
Stryker Corp
|
345.80 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
BSX
Boston Scientific Corp
|
89.70 | 132.67B | 16.75B | 1.85B | 2.37B | 1.25 |
|
MDT
Medtronic Plc
|
82.88 | 106.28B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
69.36 | 40.63B | 5.72B | 4.17B | 259.90M | 6.97 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-17 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-07 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2022-11-22 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-11-09 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2022-03-15 | 개시 | Craig Hallum | Buy |
| 2021-11-15 | 재개 | Morgan Stanley | Overweight |
| 2021-11-10 | 재개 | JP Morgan | Overweight |
| 2021-07-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-08 | 개시 | Canaccord Genuity | Buy |
| 2021-03-08 | 개시 | Goldman | Buy |
| 2021-03-08 | 개시 | JP Morgan | Overweight |
| 2021-03-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioventus Inc 주식(BVS)의 최신 뉴스
(BVS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Ensign Group Invests in Growth With New Facility Acquisitions - TradingView
Canaccord maintains Bioventus stock with $15 target, bullish outlook By Investing.com - Investing.com Australia
Canaccord maintains Bioventus stock with $15 target, bullish outlook - Investing.com India
Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Bone Growth Stimulator Market Is Booming Worldwide | Orthofix Medical Inc., Medtronic, Zimmer Biomet, Bioventus Inc - openPR.com
Charles Schwab Investment Management Inc. Grows Position in Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus CFO Mark Leonard sells $53,639 in stock By Investing.com - Investing.com Australia
Bioventus CFO Mark Leonard sells $53,639 in stock - Investing.com India
(BVS) Proactive Strategies - news.stocktradersdaily.com
Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates - MSN
Bioventus SVP Katrina Church sells shares worth $9,925 By Investing.com - Investing.com Australia
Bioventus SVP Anthony D’Adamio sells $25,496 in stock - Investing.com India
Bioventus SVP Katrina Church sells shares worth $9,925 - Investing.com India
Europe Viscosupplementation Market Projected To Witness Substantial Growth, 2025-2032: Sanofi S.A., Bioventus - EIN News
Bioventus (NYSE:BVS) Receives “Buy” Rating from Canaccord Genuity Group - Defense World
Bioventus (BVS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
How To Trade (BVS) - news.stocktradersdaily.com
Earnings call transcript: Bioventus Q4 2024 beats revenue forecast, stock surges - Investing.com Australia
Bioventus Earnings Call: Strong Growth & 2025 Outlook - TipRanks
Bioventus Inc. (NASDAQ:BVS) Q4 2024 Earnings Call Transcript - Insider Monkey
Bioventus: Strong Financial Performance and Strategic Growth Drive Buy Rating - TipRanks
Bioventus Full Year 2024 Earnings: Beats Expectations - Yahoo
Bioventus Faces Potential Stock Dilution Risk Amid Resale of 35 Million Shares - TipRanks
Bioventus Inc (BVS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ... - Yahoo Finance
Bioventus Inc (BVS) Q4 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
Bioventus Reports Strong 2024 Financial Performance - TipRanks
Bioventus: Q4 Earnings Snapshot - mySA
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results - OrthoSpineNews
Bioventus: A Medical Technology Company on the Move - RagingBull
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million - Benzinga
Bioventus Shares Rise After Improved 4Q - MarketWatch
Korn Ferry Posts Better-Than-Expected Earnings, Joins Bioventus, Endeavour Silver, Vail Resorts And Other Big Stocks Moving Higher On Tuesday - Benzinga
Bioventus Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Bioventus Inc. Reports Earnings Results for the Fourth Quarter Ended December 28, 2024 - Marketscreener.com
Bioventus sees FY25 revenue $560M-$570M, consensus $554.78M - TipRanks
Bioventus Q4 Adjusted Earnings, Revenue Rise; 2025 Outlook Set - Marketscreener.com
Bioventus stock soars 28% on upbeat FY25 guidance following Q4 revenue beat - Investing.com Australia
Bioventus stock soars 28% on upbeat FY25 guidance following Q4 revenue beat By Investing.com - Investing.com South Africa
Bioventus: Q4 Earnings Snapshot -March 11, 2025 at 07:53 am EDT - Marketscreener.com
BIOVENTUS Earnings Results: $BVS Reports Quarterly Earnings - Nasdaq
Bioventus Inc. SEC 10-K Report - TradingView
Bioventus Inc. Reports Strong Q4 and Full-Year 2024 Financial Results - TradingView
Bioventus Delivers Double-Digit Growth, Cuts Debt by $48M in Financial Turnaround - StockTitan
BIOVENTUS Earnings Preview: Recent $BVS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Bioventus Inc. (NYSE:BVS) Shares Purchased by Principal Financial Group Inc. - Defense World
Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues - Simply Wall St
Bioventus Inc (BVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
7.46%
자본화:
|
볼륨(24시간):